PIA
STML

Piedmont Investment Advisors’s Stemline Therapeutics, Inc. STML Stock Holding History

Piedmont Investment Advisors’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-480
Closed -$8K – 2737
2018
Q2 		$8K Buy
+480
New +$8.57K ﹤0.01% 1947

Other funds holding STML

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Piedmont Investment Advisors's STML Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Stemline Therapeutics, Inc. (STML) in Q3 2018, closing a stake of 480 shares — an estimated $8K sold.

Piedmont Investment Advisors first reported a position in STML in Q2 2018 and held it in 1 quarter. The position peaked at $8K in Q2 2018. 90 funds tracked by Wall St. Rank hold STML as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Stemline Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 480 Stemline Therapeutics, Inc. shares in Q3 2018, an estimated $8K.
  • Piedmont Investment Advisors first reported a position in Stemline Therapeutics, Inc. in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Stemline Therapeutics, Inc. position peaked at $8K in Q2 2018.
  • 90 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.